Audited Financial Results for the year ended 31.03.2025
Awaiting price reaction for this filing.
Uniworth International Ltd reported nil revenue from operations for FY25 as the company stated there has been 'no business activities since long.' The standalone net loss widened slightly to Rs. 157.17 lacs from Rs. 152.53 lacs in the previous year, driven mainly by finance costs of Rs. 152.99 lacs on existing borrowings. The standalone balance sheet shows a deeply negative net worth of Rs. (11,868.12) lacs against total liabilities of Rs. 15,206.17 lacs and total assets of only Rs. 3,338.05 lacs. Both standalone and consolidated auditors issued qualified opinions, flagging Rs. 3,010.57 lacs of doubtful export receivables, Rs. 227.73 lacs of doubtful bank settlement claims, Rs. 52.70 lacs of doubtful miscellaneous advances, and Rs. 5.12 lacs invested in a sick company, for which no provisions were made. On the consolidated side, the auditor of subsidiary Uniworth Biotech Ltd was denied access, creating an additional qualification. Operating cash flow was nominally positive only because current liabilities increased; underlying operations remain loss-making.
This is a deeply negative disclosure for shareholders — the company is non-operating, has a massively negative net worth, carries repeated audit qualifications on large doubtful receivables, and faces clear going-concern uncertainty. Shareholders should treat this stock as a high-risk, effectively dormant entity, and the qualified opinion may weigh on any remaining trading liquidity and investor confidence.